Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies
Open Access
- 26 June 2015
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 46 (4) , 1091-1101
Abstract
Utilizing decision making biomarkers in drug development requires thorough assay validation. Special considerations need to be taken into account when monitoring biomarkers using immunoassays in the presence of therapeutic antibodies. We have developed robust and sensitive assays to assess target engagement and proof of mechanism to support the clinical progression of a human monoclonal antibody against the neurotoxic amyloid-β (Aβ) 42 peptide. Here we present the introduction of novel pre-treatment steps to ensure drug-tolerant immunoassays and describe the validation of the complete experimental procedures to measure total Aβ 42 concentration (bound and unbound) in cerebrospinal fluid (CSF) and plasma, free Aβ 42 concentration (unbound) in CSF, and Aβ 40 concentration in CSF. The difference in composition of the matrices (CSF and plasma) and antigen levels therein, in combination with the hydrophobic properties of Aβ protein, adds to the complexity of validation. Monitoring pharmacodynamics of an Aβ 42 specific monoclonal antibody in a non-human primate toxicology study using these assays, we demonstrated a 1500-fold and a 3000-fold increase in total Aβ 42 in plasma, a 4-fold and 8-fold increase in total Aβ 42 in CSF together with a 95% and 96% reduction of free Aβ 42 in CSF following weekly intravenous injections of 10 mg/kg and 100 mg/kg, respectively. Levels of Aβ 40 were unchanged. The accuracy of these data is supported by previous pre-clinical studies as well as predictive pharmacokinetic/pharmacodynamics modeling. In contrast, when analyzing the same non-human primate samples excluding the pre-treatment steps, we were not able to distinguish between free and total Aβ 42 . Our data clearly demonstrate the importance of thorough evaluation of antibody interference and appropriate validation to monitor different types of biomarkers in the presence of a therapeutic antibody.Keywords
This publication has 14 references indexed in Scilit:
- Alzheimer disease immunotherapeutics: Then and nowHuman Vaccines & Immunotherapeutics, 2014
- Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012Expert Opinion on Therapeutic Patents, 2013
- Validation of Assays for Measurement of Amyloid-β Peptides in Cerebrospinal Fluid and Plasma Specimens from Patients with Alzheimer's Disease Treated with SolanezumabJournal of Alzheimer’s Disease, 2013
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer DiseaseArchives of Neurology, 2012
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive declineNature, 2012
- Solanezumab for the treatment of mild-to-moderate Alzheimer’s diseaseExpert Review of Clinical Immunology, 2012
- Developing β‐secretase inhibitors for treatment of Alzheimer’s diseaseJournal of Neurochemistry, 2011
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- BapineuzumabExpert Opinion on Biological Therapy, 2010
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002